Measuring Endogenous 5-HT Release by Emission Tomography: Promises and Pitfalls
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Molecular in vivo neuroimaging techniques can be used to measure regional changes in endogenous neurotransmitters, evoked by challenges that alter synaptic neurotransmitter concentration. This technique has most successfully been applied to the study of endogenous dopamine release using positron emission tomography, but has not yet been adequately extended to other neurotransmitter systems. This review focuses on how the technique has been applied to the study of the 5-hydroxytryptamine (5-HT) system. The principles behind visualising fluctuations in neurotransmitters are introduced, with reference to the dopaminergic system. Studies that aim to image acute, endogenous 5-HT release or depletion at 5-HT receptor targets are summarised, with particular attention to studies in humans. Radiotracers targeting the 5-HT 1A , 5-HT 2A , and 5-HT 4 receptors and the serotonin reuptake transporter have been explored for their sensitivity to 5-HT fluctuations, but with mixed outcomes; tracers for these targets cannot reliably image endogenous 5-HT in humans. Shortcomings in our basic knowledge of the mechanisms underlying changes in binding potential are addressed, and suggestions are made as to how the selection of targets, radiotracers, challenge paradigms, and experimental design might be optimised to improve our chances of successfully imaging endogenous neurotransmitters in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955
Self-citationValvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632 · cited 1×
“Fenfluramine, despite being an efficient way to increase 5-HT in animals, cannot readily be administered to human subjects in high doses (Connolly et al, 1997), although one study has now published preliminary findings using an oral dose to increase brain 5-HT (Hasler et al, 2009).”
ResultIncreased baseline occupancy of D 2 receptors by dopamine in schizophrenia
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.8104 · Cited by 1,020 · cited 3×
“Under baseline conditions, 10% of RHIGH are occupied by dopamine (Abi-Dargham et al, 2000), leaving 40% available to further DA occupancy.”
BackgroundMethodImaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review
Laruelle, M. (2000) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200003000-00001 · Cited by 944
Serotonin model of schizophrenia: emerging role of glutamate mechanisms
Aghajanian, G. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00046-6 · Cited by 529 · cited 1×
“…study showed that [ 18 F]altanserin was not sensitive to changes in 5-HT induced by ketamine in healthy volunteers (Matusch et al, 2007), although ketamine is primarily an N-methyl-D-aspartic acid antagonist and D2 agonist with secondary effects on the 5-HT system (Aghajanian and Marek, 2000).”
BackgroundPharmacological characterization of selective serotonin reuptake inhibitors (SSRIs)
Hyttel, J. (1994) · International Clinical Psychopharmacology · doi:10.1097/00004850-199403001-00004 · Cited by 492 · cited 2×
“For example, the potential for interaction of clomipramine with 5-HT 1A and 5- HT 2A receptors (Hyttel, 1994), norfenfluramine with 5-HT 2A receptors (Rothman and Baumann, 2002) and amphetamine, a proposed metabolite of tranylcypromine , with SERT (Sherry et al, 2000; Youdim et al, 1979) could have…”
BackgroundInactivation of 5-HT2C Receptors Potentiates Consequences of Serotonin Reuptake Blockade
Cremers, T. I. F. H., Giorgetti, M., Bosker, F. J., Hogg, S., Arnt, J., Mørk, A., Honig, G., Bøgesø, K.-P., Westerink, B. H. C., den Boer, H., et al. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300474 · Cited by 157
Willeit, M., Ginovart, N., Graff, A., Rusjan, P., Vitcu, I., Houle, S., Seeman, P., Wilson, A. A., & Kapur, S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301400 · Cited by 107 · cited 2×
“Nonselective ligands such as the D2/D3 agonist tracer [ 11 C]( + )PHNO (Willeit et al, 2008) and M1/M2 muscarinic acetylcholinergic ligand [ 11 C]3-PPB (Nishiyama et al, 2001; Tsukada et al, 2004) seem to be able to show dopamine and acetylcholine release, respectively.”
BackgroundSkinbjerg, M., Liow, J.-S., Seneca, N., Hong, J., Lu, S., Thorsell, A., Heilig, M., Pike, V. W., Halldin, C., Sibley, D. R., et al. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.01.055 · Cited by 86
Cited by
Serotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739
Self-citationA High-Resolution In Vivo Atlas of the Human Brain's Serotonin System
Beliveau, V., Ganz, M., Feng, L., Ozenne, B., Højgaard, L., Fisher, P. M., Svarer, C., Greve, D. N., & Knudsen, G. M. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2830-16.2016 · Cited by 368
“However, because the occupancy of endogenous 5-HT is low for most targets (Paterson et al., 2010), it is unlikely that individual differences in endogenous 5-HT (and thereby in vivo affinity) would incur any bias.”
BackgroundSelf-citationAndrews, P. W., Bharwani, A., Lee, K. R., Fox, M., & Thomson, J. A. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.01.018 · Cited by 281
“…165 18.3 – 10.7 785 These techniques can measure dynamic changes in neurotransmission induced by pharmacological or physiological challenges if radiotracers measuring monoamine receptor or transporter density are sensitive to changes in endogenous monoamine levels (Paterson et al., 2010, 2013).”
BackgroundInfluentialEttrup, A., Hansen, M., Santini, M. A., Paine, J., Gillings, N., Palner, M., Lehel, S., Herth, M. M., Madsen, J., Kristensen, J., et al. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1686-8 · Cited by 128
“Dopamine D2 receptor agonist radiotracers are superior to antagonist radiotracers for measuring dopamine release in vivo in humans [13], monkeys [14] and mice [9], and since several studies have failed to demonstrate that 5-HT2A receptor antagonist PET tracers are displaceable by elevated levels of endogenous 5-HT [15…”
BackgroundSelf-citationSerotonin and molecular neuroimaging in humans using PET
Saulin, A., Savli, M., & Lanzenberger, R. (2012) · Amino Acids · doi:10.1007/s00726-011-1078-9 · Cited by 113
Metadata
- Authors
- Paterson, L. M., Tyacke, R. J., Nutt, D. J., & Knudsen, G. M.
- Venue
- Journal of Cerebral Blood Flow & Metabolism
- Publisher
- SAGE Publications
- Published
- 2010-07-28
- Volume
- 30
- Issue
- 10
- Pages
- 1682-1706
- ISSN
- 0271-678X (ISSN-L)
- 1559-7016
- OpenAlex
- W2033543819
- Cited by
- 145
- References
- 9
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.